15.14

0.23% -0.04

Takeda Pharmaceutical Co Adr (TAK)

Overview News Price History Option Chain Discussions Forecast Dividend History

Takeda Pharmaceutical Co Adr stock is traded at $15.14, with a volume of 784.40K. It is down -0.23% in the last 24 hours and up +0.90% over the past month. Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Previous Close:

$15.18

Open:

$15.01

24h Volume:

784.40K

Relative Volume:

0.42

Market Cap:

$46.11B

Revenue:

$30.25B

Net Income/Loss:

$1.37B

P/E Ratio:

35.56

EPS:

0.4257

Net Cash Flow:

$5.08B

1W Performance:

+2.96%

1M Performance:

+0.90%

6M Performance:

+9.75%

1Y Performance:

+14.47%

1-Day Range:

$14.95

$15.15

1-Week Range:

$14.81

$15.34

52-Week Range:

$12.57

$15.37

Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile

Name

Takeda Pharmaceutical Co Adr

Sector

Healthcare (1155)

Industry

Drug Manufacturers - Specialty & Generic (1)

Phone

Address

Employee

49,281

Twitter

@takedapharma

Next Earnings Date

2024-10-31

Latest SEC Filings

TAK's Discussions on Twitter

Compare TAK with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TAK Takeda Pharmaceutical Co Adr	15.14	46.11B	30.25B	1.37B	5.08B	0.4257
ZTS Zoetis Inc	152.04	65.46B	9.26B	2.49B	2.30B	5.47
HLN Haleon Plc Adr	10.28	45.84B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	14.54	16.37B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	297.41	12.81B	2.76B	1.11B	898.10M	22.77

Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-02-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-16-23	Upgrade	BofA Securities	Neutral → Buy
Jul-19-22	Upgrade	Cowen	Market Perform → Outperform
Oct-07-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-19-21	Downgrade	JP Morgan	Overweight → Neutral
Nov-01-19	Initiated	Cowen	Market Perform
Aug-15-19	Downgrade	Daiwa Securities	Outperform → Neutral

View All

Takeda Pharmaceutical Co Adr Stock (TAK) Latest News

Apr 22, 2025

Analyzing Takeda Pharmaceutical Co ADR (TAK) After Recent Trading Activity - knoxdaily.com

Apr 22, 2025

Cintas Corporation [CTAS] Insider Activity: An Update for Investors - knoxdaily.com

Apr 22, 2025

Apr 16, 2025

TAK vs. DSNKY: Which Stock Is the Better Value Option? - Yahoo Finance

Apr 16, 2025

Apr 10, 2025

Biopharmaceuticals Global Overview Report 2025: Global Market to Reach $698.7 Billion by 2030, Fueled by Specialized Therapies, Such as mAb and Gene Treatments, & a Strong Pipeline - GlobeNewswire Inc.

Apr 10, 2025

Apr 09, 2025

Asian Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading - MSN

Apr 09, 2025

Apr 03, 2025

Vital Energy Inc (VTLE) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle

Mar 14, 2025

China Liberal Education Holdings Ltd: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle

Mar 14, 2025

Takeda Pharmaceutical Stock (NYSE: TAK): Strategic Focus on Oncology and Growth Opportunities - Value the Markets

Mar 14, 2025

Mar 13, 2025

Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds - Seeking Alpha

Mar 13, 2025

Mar 10, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Mar 10, 2025

Mar 06, 2025

Charles Schwab Trying To Close In On Key Technical Measure - Inkl

Mar 06, 2025

Mar 04, 2025